Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Ratio-based decisions and the quantitative analysis of cDNA microarray images.

Chen Y, Dougherty ER, Bittner ML.

J Biomed Opt. 1997 Oct;2(4):364-74. No abstract available.

PMID:
23014960
2.

ErbB2 activation of ESX gene expression.

Neve RM, Ylstra B, Chang CH, Albertson DG, Benz CC.

Oncogene. 2002 May 30;21(24):3934-8.

3.

Molecular characterisation of soft tissue tumours: a gene expression study.

Nielsen TO, West RB, Linn SC, Alter O, Knowling MA, O'Connell JX, Zhu S, Fero M, Sherlock G, Pollack JR, Brown PO, Botstein D, van de Rijn M.

Lancet. 2002 Apr 13;359(9314):1301-7.

PMID:
11965276
4.

Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients.

Ladanyi M, Antonescu CR, Leung DH, Woodruff JM, Kawai A, Healey JH, Brennan MF, Bridge JA, Neff JR, Barr FG, Goldsmith JD, Brooks JS, Goldblum JR, Ali SZ, Shipley J, Cooper CS, Fisher C, Skytting B, Larsson O.

Cancer Res. 2002 Jan 1;62(1):135-40.

5.

Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter?

Hoeflich A, Reisinger R, Lahm H, Kiess W, Blum WF, Kolb HJ, Weber MM, Wolf E.

Cancer Res. 2001 Dec 15;61(24):8601-10. Review. No abstract available.

6.

SYT associates with human SNF/SWI complexes and the C-terminal region of its fusion partner SSX1 targets histones.

Kato H, Tjernberg A, Zhang W, Krutchinsky AN, An W, Takeuchi T, Ohtsuki Y, Sugano S, de Bruijn DR, Chait BT, Roeder RG.

J Biol Chem. 2002 Feb 15;277(7):5498-505. Epub 2001 Dec 4. Erratum in: J Biol Chem 2002 Apr 19;277(16):14350.

7.

E-cadherin gene mutations frequently occur in synovial sarcoma as a determinant of histological features.

Saito T, Oda Y, Sugimachi K, Kawaguchi K, Tamiya S, Tanaka K, Matsuda S, Sakamoto A, Iwamoto Y, Tsuneyoshi M.

Am J Pathol. 2001 Dec;159(6):2117-24.

8.

MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia.

Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD, Sallan SE, Lander ES, Golub TR, Korsmeyer SJ.

Nat Genet. 2002 Jan;30(1):41-7. Epub 2001 Dec 3.

PMID:
11731795
9.

HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation.

Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC.

Nat Cell Biol. 2001 Nov;3(11):973-82. Erratum in: Nat Cell Biol 2002 Sep;4(9):736.

PMID:
11715018
10.

Fusions of the SYT and SSX genes in synovial sarcoma.

Ladanyi M.

Oncogene. 2001 Sep 10;20(40):5755-62. Review.

11.

High Ki-67 proliferative index predicts disease specific survival in patients with high-risk soft tissue sarcomas.

Hoos A, Stojadinovic A, Mastorides S, Urist MJ, Polsky D, Di Como CJ, Brennan MF, Cordon-Cardo C.

Cancer. 2001 Aug 15;92(4):869-74.

PMID:
11550160
12.

c-KIT and c-KIT ligand (SCF) in synovial sarcoma (SS): an mRNA expression analysis in 23 cases.

Tamborini E, Papini D, Mezzelani A, Riva C, Azzarelli A, Sozzi G, Pierotti MA, Pilotti S.

Br J Cancer. 2001 Aug 3;85(3):405-11.

13.

Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks.

Khan J, Wei JS, Ringnér M, Saal LH, Ladanyi M, Westermann F, Berthold F, Schwab M, Antonescu CR, Peterson C, Meltzer PS.

Nat Med. 2001 Jun;7(6):673-9.

14.

Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients.

Trassard M, Le Doussal V, Hacène K, Terrier P, Ranchère D, Guillou L, Fiche M, Collin F, Vilain MO, Bertrand G, Jacquemier J, Sastre-Garau X, Bui NB, Bonichon F, Coindre JM.

J Clin Oncol. 2001 Jan 15;19(2):525-34.

PMID:
11208847
15.

Molecular mechanisms underlying ErbB2/HER2 action in breast cancer.

Harari D, Yarden Y.

Oncogene. 2000 Dec 11;19(53):6102-14. Review.

16.

Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques.

Sallinen SL, Sallinen PK, Haapasalo HK, Helin HJ, Helén PT, Schraml P, Kallioniemi OP, Kononen J.

Cancer Res. 2000 Dec 1;60(23):6617-22.

17.

Molecular mechanisms underlying human synovial sarcoma development.

dos Santos NR, de Bruijn DR, van Kessel AG.

Genes Chromosomes Cancer. 2001 Jan;30(1):1-14. Review.

PMID:
11107170
18.

Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment.

Spillane AJ, A'Hern R, Judson IR, Fisher C, Thomas JM.

J Clin Oncol. 2000 Nov 15;18(22):3794-803.

PMID:
11078492
19.

Contactin-associated protein (Caspr) and contactin form a complex that is targeted to the paranodal junctions during myelination.

Rios JC, Melendez-Vasquez CV, Einheber S, Lustig M, Grumet M, Hemperly J, Peles E, Salzer JL.

J Neurosci. 2000 Nov 15;20(22):8354-64.

20.

Patterns of keratin polypeptides in 110 biphasic, monophasic, and poorly differentiated synovial sarcomas.

Miettinen M, Limon J, Niezabitowski A, Lasota J.

Virchows Arch. 2000 Sep;437(3):275-83.

PMID:
11037348

Supplemental Content

Support Center